Wednesday, September 30, 2015

BWI: GlaxoSmithKline Pharmaceuticals Completes Transaction with Novartis

 
Source : GlaxoSmithKline Pharmaceuticals Limited (GSK India)
Wednesday, September 30, 2015 6:11PM IST (12:41PM GMT)
 
GlaxoSmithKline Pharmaceuticals Completes Transaction with Novartis
 
Mumbai, Maharashtra, India

GlaxoSmithKline Pharmaceuticals Ltd. (‘GSK India’) announces completion of its transaction with Novartis Healthcare Pvt. Ltd. (‘Novartis India’) today where GSK India acquires Novartis’ vaccines business and divests its marketed oncology portfolio to Novartis India.
 
This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 on the same basis.
 
The acquisition of the vaccines business of Novartis provides GSK with an exciting opportunity to build an even stronger, sustainable global vaccines business. The transaction will enhance GSK’s vaccines portfolio and bring together its expertise in virology, bacterial infection and technological platforms to deliver a reliable supply of high quality vaccines.
 
About GlaxoSmithKline:
 
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For more information, visit www.gsk-india.com.
 

 
Media Contact Details

Ransom D'Souza, India Media enquiries +91-9820234999 ,

Simon Steel, UK Media enquiries +44 (0) 20 8047 5502 ,

 

To ensure that you continue to receive email from Business Wire India in your inbox, please add businesswireindia.com to your Address Book or Safe List.

 
To submit a press release, click here.
To unsubscribe or modify your Business Wire India settings, please visit your profile page on Business Wire India.

Connect with us on: Facebook | Twitter | Google+
 
 

No comments:

Post a Comment